Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial.

[1]  R. Sutter,et al.  Immunogenicity of a new routine vaccination schedule for global poliomyelitis prevention: an open-label, randomised controlled trial , 2015, The Lancet.

[2]  S. Self,et al.  Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. , 2015, The Lancet. Infectious diseases.

[3]  Walter A Orenstein,et al.  Polio vaccination: past, present and future. , 2015, Future microbiology.

[4]  R. Sutter,et al.  Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. , 2014, The Journal of infectious diseases.

[5]  G. Kang,et al.  Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial , 2014, The Lancet.

[6]  N. Grassly,et al.  Efficacy of inactivated poliovirus vaccine in India , 2014, Science.

[7]  G. Kang,et al.  Eff ect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine : an open-label , randomised controlled trial , 2014 .

[8]  R. Sutter,et al.  Priming after a fractional dose of inactivated poliovirus vaccine. , 2013, The New England journal of medicine.

[9]  N. Grassly,et al.  Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge , 2012, PLoS pathogens.

[10]  R. Sutter,et al.  Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial , 2010, The Lancet.

[11]  M. Pallansch,et al.  Fractional doses of inactivated poliovirus vaccine in Oman. , 2010, The New England journal of medicine.

[12]  Miguel A. Galindo,et al.  Randomized, Placebo-Controlled Trial of Inactivated Poliovirus Vaccine in Cuba , 2007 .

[13]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[14]  R. Handsher,et al.  Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule , 1989, European Journal of Epidemiology.

[15]  C. Meschievitz,et al.  Fifteen years of experience with Vero-produced enhanced potency inactivated poliovirus vaccine. , 1997, The Pediatric infectious disease journal.

[16]  C. Beuvery,et al.  Comparison of enhanced potency inactivated poliovirus vaccine (EIPV) versus standard oral poliovirus vaccine (OPV) in Thai infants. , 1994, Scandinavian journal of infectious diseases.

[17]  P. Minor,et al.  Antigenic structure of poliovirus in inactivated vaccines. , 1993, The Journal of general virology.

[18]  P. Minor,et al.  WHO Expert Committee on Biological Standardization. , 2004, World Health Organization technical report series.

[19]  K. Lapinleimu,et al.  Antigen content of inactivated poliovirus vaccine for use in a one- or two-dose regimen. , 1982, Annals of clinical research.

[20]  K. Lapinleimu,et al.  Theoretical and practical considerations in the application of killed poliovirus vaccine for the control of paralytic poliomyelitis. , 1981, Developments in biological standardization.

[21]  P. Saliou,et al.  Killed poliovirus antigen titration in humans. , 1978, Developments in biological standardization.